摘要
目的研究免疫组化在低分化胆管细胞癌和肝细胞癌(Hepatic Cell Carcinoma,HCC)鉴别中的应用价值。方法选择2018年1月~2021年1月期间收治的肝癌患者78例进行研究,包括低分化胆管细胞癌21例,HCC患者50例,低分化胆管细胞癌合并HCC患者7例,均进行免疫组化检测,分析三种患者中CK-19、GPC-3检出情况,以及不同分化患者检出情况。结果HCC患者中CK-19均为阴性(0.00%),低分化胆管细胞癌中有19例(90.48%)CK-19阳性,低分化胆管细胞癌合并HCC患者CK-19均为阳性(100.00%),三者之间存在明显差异(P<0.05);HCC患者GPC-3阳性为45例(90.00%),低分化胆管细胞癌GPC-3阳性为4例(19.05%),低分化胆管细胞癌合并HCC GPC-3阳性7例(100.00%),三者之间存在明显差异(P<0.05)。低分化患者中CK-19表达阳性率为5例(35.71%),中分化患者中CK-19阳性率为10例(23.81%),高于高分化患者的1例(4.55%),差异有统计学意义(P<0.05)。GPC-3在低分化患者中阳性率11例(78.57%),中分化患者阳性率30例(71.43%),高分化患者阳性率16例(72.73%),三组之间差异无统计学意义(P>0.05)。结论CK-19、GPC-3对肝细胞癌、低分化胆管细胞癌具有良好的诊断价值,GPC-3在肝细胞癌中呈现高表达,而CK-19仅在胆管细胞癌表达,联合检测CK-19、GPC-3对鉴别肝细胞癌与胆管细胞癌具有重要价值。
Objective To study the applied value of immunohistochemical panel on the identification of poorly differentiated cholangiocellular carcinoma and hepatic cell carcinoma(HCC).Methods 78 liver cancer patients(2018.01~2021.01)were selected,including 21 poorly differentiated cholangiocellular carcinoma cases,50 HCC cases,and 7 poorly differentiated cholangiocellular carcinoma cases with HCC.The immunohistochemical panel was used to analyze cytokeratin-19(CK-19)and glypican-3(GPC-3)detection conditions,and the detection of patients with different differentiation.Results Positive rates of CK-19 in HCC patients were 0.00%,90.48%in poorly differentiated cholangiocellular carcinoma patients(19 cases)and 100.00%in poorly differentiated cholangiocellular carcinoma patients with HCC(P<0.05).Positive rates of GPC-3 in HCC patients were 90.00%(45 cases),19.05%in poorly differentiated cholangiocellular carcinoma patients(4 cases)and 100.00%in poorly differentiated cholangiocellular carcinoma patients with HCC(7 cases);the differences were statistically significant(P<0.05).Positive rates of CK-19 in poorly differentiated cases(35.71%/5 cases)and moderately differentiated cases(23.81%/10 cases)were higher than highly differentiated cases(4.55%/one case),with statistically significant difference(P<0.05).There were no significant differences about the positive rates of GPC-3 in poorly differentiated cases(78.57%/11 cases),moderately differentiated cases(71.43%/30 cases)and highly differentiated cases(72.73%/16 cases)(P>0.05).Conclusion CK-19 and GPC-3 has high diagnosis value of HCC and poorly differentiated cholangiocellular carcinoma;GPC-3 is highly expressed in HCC tissue while CK-19 is only expressed in cholangiocellular carcinoma tissue;the combined examination of CK-19 and GPC-3 is applicable to identify the HCC and cholangiocellular carcinoma.
作者
李成之
LI Cheng-zhi(Pathology Department,Taishan People’s Hospital,Taishan 529200,China)
出处
《中国处方药》
2022年第1期169-171,共3页
Journal of China Prescription Drug
关键词
免疫组化
低分化胆管细胞癌
肝细胞癌
鉴别
Immunohistochemical panel
Poorly differentiated cholangiocellular carcinoma
Hepatic cell carcinoma
Identification
